Troculeucel

托古仑赛

Report date: 2025/03/10 14:28:10

Base Information

Drug NameTroculeucel
Drug Alias NameSNK-01SNK01
ClassificationCell and gene therapy > Cell therapy > Donor > AutologousCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > Natural killer cell therapyCell and gene therapy > Cell therapy > Source of cells > Peripheral blood-derived
Mechanisms of ActionNatural killer cell replacementsImmunologic cytotoxicity
TargetsUpdating
Therapy Area/IndicationsPlaque psoriasisSolid tumoursNeurodegenerative Diseases +[19] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesMexico +[4] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesNKGen Biotech Inc
China Registration ClassN/A

Develop Information

Active CompaniesParkinson'S FoundationNKGen Biotech Inc
Inactive CompaniesNKMAX Co Ltd
Active IndicationsAlzheimer Disease
Inactive IndicationsPlaque psoriasisSolid tumoursNeurodegenerative Diseases +[18] 

Other Information

ATC CodeN/A
Related LinksN/A